Literature DB >> 21352467

Phosphorus dynamics during hemodialysis.

Carl M Kjellstrand1, Todd S Ing, Per T Kjellstrand, Ingegerd Odar-Cederlof, Chris R B Lagg.   

Abstract

We studied phosphorus (P) dynamics and its relation to urea dynamics in a wide range of dialyses by measuring predialysis and postdialysis serum P levels and all removed P and urea in dialysate during 455 hemodialyses. Dialyses were performed at different frequencies (range 3-6 treatments/wk); duration of dialysis (t) (range 80-560 minutes), varied blood and dialysate flow, and with high-flux and low-flux membranes. Kt/V-P, Kt/V-urea, weekly removal of P-and urea and removal volumes (Vr) and their relationships to varying dialyses, and predialysis concentrations, and protein catabolic rates were studied in linear and multiple regression analyses. A weekly dialysis time of > 30 hours was needed to maintain serum P concentration normal without the use of phosphate binders. Vr-P as a percentage of body weight was dependent on predialysis serum P and increased steeply as predialysis serum P decreased and dialysis time was prolonged. There was no relationship between Vr-urea and Vr-P. Phosphorus removal per week was mainly dependent on weekly frequency, and time on dialysis and > 38 h/wk were necessary to remove the recommended P intake. Phosphorus shows highly variable dynamics during dialysis. The body maintains extracellular P concentration by releasing P from large compartments when the dialysis time is prolonged and the serum concentration of P decreases during dialysis. Vr-P shows huge variation between patients and in an individual patient, depending on predialysis serum P. Kt/V is inaccurate in describing P removal. To remove P efficiently, it is most important to perform long and more frequent hemodialysis.
© 2011 The Authors. Hemodialysis International © 2011 International Society for Hemodialysis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21352467     DOI: 10.1111/j.1542-4758.2011.00538.x

Source DB:  PubMed          Journal:  Hemodial Int        ISSN: 1492-7535            Impact factor:   1.812


  6 in total

1.  What can we learn from the saga of chitosan gums in hyperphosphatemia therapy?

Authors:  Man S Oh; Jaime Uribarri
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-09       Impact factor: 8.237

Review 2.  Controversies in the Management of Secondary Hyperparathyroidism in Chronic Kidney Disease.

Authors:  Ezequiel Bellorin-Font; George Vasquez-Rios; Kevin J Martin
Journal:  Curr Osteoporos Rep       Date:  2019-10       Impact factor: 5.096

3.  The adequacy of phosphorus binder prescriptions among American hemodialysis patients.

Authors:  Anne M Huml; Catherine M Sullivan; Janeen B Leon; Ashwini R Sehgal
Journal:  Ren Fail       Date:  2012-09-26       Impact factor: 2.606

Review 4.  Phosphate balance in ESRD: diet, dialysis and binders against the low evident masked pool.

Authors:  A Galassi; A Cupisti; A Santoro; M Cozzolino
Journal:  J Nephrol       Date:  2014-09-23       Impact factor: 3.902

5.  Hypophosphatemia in critically ill patients with acute kidney injury treated with hemodialysis is associated with adverse events.

Authors:  Cynthia Lim; Han Khim Tan; Manish Kaushik
Journal:  Clin Kidney J       Date:  2017-01-05

6.  Nephrologists' perspectives on dialysis treatment: results of an international survey.

Authors:  Richard J Fluck; Denis Fouque; Robert S Lockridge
Journal:  BMC Nephrol       Date:  2014-01-15       Impact factor: 2.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.